IN THE SPOTLIGHT

Tarlatamab in Combination Therapy: Future Potential for SCLC

Tarlatamab in Combination Therapy: Future Potential for SCLC

Adverse Event Management: CRS and ICANS with Tarlatamab

Adverse Event Management: CRS and ICANS with Tarlatamab

Fox Chase Cancer Center Researchers Find Gene That Triggers Immune Response in Treatment-Resistant Small-Cell Lung Cancer

Fox Chase Cancer Center Researchers Find Gene That Triggers Immune Response in Treatment-Resistant Small-Cell Lung Cancer

Immunotherapy Instills Renewed Promise in SCLC

Immunotherapy Instills Renewed Promise in SCLC

Durvalumab Consolidation Extends Survival in LS-SCLC, ADRIATIC Findings Show

Durvalumab Consolidation Extends Survival in LS-SCLC, ADRIATIC Findings Show

Ponsegromab Could Offer Further Treatment for Cancer Cachexia

Ponsegromab Could Offer Further Treatment for Cancer Cachexia

Novel Agent Effective for Cancer Wasting Disorder

Novel Agent Effective for Cancer Wasting Disorder

FDA Grants Breakthrough Status To GSKs Lung Cancer Drug

FDA Grants Breakthrough Status To GSKs Lung Cancer Drug

Imfinzi Granted Priority Review and Breakthrough Therapy Designation for Limited-Stage Small Cell Lung Cancer in the US

Imfinzi Granted Priority Review and Breakthrough Therapy Designation for Limited-Stage Small Cell Lung Cancer in the US

Durvalumab Gets Priority Review for Limited-Stage Small Cell Lung Cancer

Durvalumab Gets Priority Review for Limited-Stage Small Cell Lung Cancer